The current Hemophilia A therapeutic treatment mainly consists of protein replacement, requiring frequent prophylactic or on-demand parenteral administrations of recombinant FVIII (r-FVIII) with an extended half-life or plasma-derived FVIII (Powell et al., 2012). This evidence concerns the gene F8 and hemophilia A.